Testing by SinoPharm Group is “in the last kilometre of a long march” Liu Jingzhen said at a news conference.
He gave no indication when results are expected.
China’s fledgling drug industry is part of a global race to produce a vaccine and has four candidates in the final stages of testing.
Health experts say, however, that even if China succeeds, stringent certification rules in Europe, the United States and Japan might mean its vaccine can only be distributed in developing countries.
SinoPharm is testing two vaccines in countries including Egypt, Argentina, Jordan and Peru, Mr Liu said.
Both are inactivated, meaning they use a non-infectious version of coronavirus.
According to Mr Liu, production lines for vaccines are being set up in Beijing and Wuhan, the city in central China where the outbreak began in December.
The production capacity will reach one billion doses next year, ensuring sufficient safety
“The production capacity will reach one billion doses next year, ensuring sufficient safety,” Mr Liu said.
Chinese-developed vaccines have been tested on 60,000 people with “only slight adverse effects” said Tian Baoguo, an official of the Ministry of Science and Technology.
Thousands of people in China, including healthcare workers and others deemed to be at risk, have been given the vaccines, while three city governments have announced plans to inoculate members of the public who need it.
